Antipsychotic Drugs Market Size, Share, and Growth Analysis, By Therapeutic Class (First Generation, Second Generation), By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Distribution Channel, By Region - Industry Forecast 2025-2032
항정신병제 시장 규모는 2023년 172억 7,000만 달러로 평가되며, 2024년 182억 7,000만 달러에서 2032년 286억 9,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 5.8%의 CAGR로 성장할 것으로 예상됩니다.
세계 항정신병제 시장은 정신건강 문제에 대한 인식이 높아지고 조기 진단 및 치료를 촉진하기 위한 정부와 의료기관의 협력적 노력에 힘입어 강력한 성장세를 보이고 있습니다. 조현병, 양극성 장애와 같은 정신질환의 증가는 1세대 및 2세대 항정신병제의 수요를 견인하고 있습니다. 지속형 주사제(LAI)와 약리유전체학을 통한 맞춤형 치료의 혁신은 환자의 순응도와 치료 결과를 개선하고 있습니다. 또한, 실시간 인사이트를 제공하는 디지털 치료제의 부상과 함께 비정형 항정신병제로의 전환을 경험하고 있습니다. 존슨앤드존슨의 150억 달러 규모의 Intra-Cellular Therapies 인수와 같은 최근 인수 및 FDA 승인은 정신과 치료의 발전과 보다 안전하고 효과적인 치료법에 대한 수요 증가에 대응하기 위한 전략적 투자의 하이라이트입니다.
목차
소개
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장 가정과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porters 분석
주요 시장 인사이트
- 핵심성공요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 사례 연구
- 규제 상황
- 특허 분석
항정신병제 시장 규모 : 치료 클래스별 & CAGR(2025-2032년)
항정신병제 시장 규모 : 질환별 & CAGR(2025-2032년)
- 시장 개요
- 정신분열증
- 양극성 장애
- 단극성 우울증
- 치매
- 기타 질환
항정신병제 시장 규모 : 약제별 & CAGR(2025-2032년)
- 시장 개요
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Brexpiprazole
- Paliperidone Palmitate
- 기타
항정신병제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)
- 시장 개요
- 병원 약국
- 드럭스토어와 약국
- 온라인 약국
항정신병제 시장 규모 : 지역별 & CAGR(2025-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5개사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채용한 전략
- 최근의 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 상세
- 제품 포트폴리오 분석
- 기업 부문별 점유율 분석
- 매출 전년비 비교(2022-2024년)
주요 기업 개요
- Johnson & Johnson(USA)
- Otsuka Pharmaceutical Co., Ltd.(Japan)
- Pfizer Inc.(USA)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Eli Lilly and Company(USA)
- AstraZeneca plc(UK)
- GlaxoSmithKline plc(UK)
- AbbVie Inc.(USA)
- Bristol-Myers Squibb(USA)
- H. Lundbeck A/S(Denmark)
- Sumitomo Pharma Co., Ltd.(Japan)
- Alkermes plc(Ireland)
- Dr. Reddy's Laboratories(India)
- Amgen Inc.(USA)
- Sanofi S.A.(France)
- Merck & Co., Inc.(USA)
- Novartis International AG(Switzerland)
- Roche Holding AG(Switzerland)
- Takeda Pharmaceutical Company Limited(Japan)
- Sun Pharmaceutical Industries Ltd.(India)
결론과 제안
ksm
Antipsychotic Drugs Market size was valued at USD 17.27 billion in 2023 and is poised to grow from USD 18.27 billion in 2024 to USD 28.69 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).
The global antipsychotic drugs market is witnessing robust growth, fueled by increased awareness of mental health issues and concerted efforts from governments and health organizations to promote early diagnosis and treatment. The rise in mental health disorders, such as schizophrenia and bipolar disorder, is driving demand for both first- and second-generation antipsychotic medications. Innovations in long-acting injectables (LAIs) and tailored therapies through pharmacogenomics are enhancing patient adherence and treatment outcomes. The market is also experiencing a shift towards atypical antipsychotics, coupled with the rise of digital therapeutics that provide real-time insights. Recent acquisitions and FDA approvals, such as Johnson & Johnson's $15 billion acquisition of Intra-Cellular Therapies, highlight strategic investments aimed at advancing psychiatric care and accommodating the growing demand for safer, effective treatments.
Top-down and bottom-up approaches were used to estimate and validate the size of the Antipsychotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Antipsychotic Drugs Market Segments Analysis
Global Antipsychotic Drugs Market is segmented by Therapeutic Class, Disease, Drug, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Drug, the market is segmented into Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Antipsychotic Drugs Market
A significant factor fueling the growth of the global antipsychotic drugs market is the escalating incidence of mental health disorders, such as schizophrenia and bipolar disorder. As awareness of these conditions rises, there is a growing demand for innovative treatment options as well as improved access to psychiatric care across the globe. This heightened understanding of mental health issues not only drives the development of new therapies but also emphasizes the necessity for comprehensive support systems for individuals affected by these disorders. Consequently, this trend is propelling the expansion of the antipsychotic drug market worldwide.
Restraints in the Antipsychotic Drugs Market
The global antipsychotic drugs market faces notable restraints, primarily due to regulatory challenges and protracted approval processes. These stringent regulations and extended clinical trial requirements hinder the timely introduction of new therapies, thereby impeding the speed at which groundbreaking medications can become available to patients. Such obstacles particularly affect market expansion in regions with rigid regulatory environments, further constraining the overall growth potential of the antipsychotic drug sector. Consequently, manufacturers and stakeholders must navigate these regulatory complexities, which can significantly delay the development and commercialization of innovative treatment options for mental health disorders.
Market Trends of the Antipsychotic Drugs Market
The antipsychotic drugs market is experiencing a notable trend towards the increasing demand for long-acting injectable antipsychotics, driven by the need for improved management of chronic psychiatric disorders such as schizophrenia. These innovative formulations allow for reduced dosing frequency, enhancing patient adherence and overall treatment effectiveness. Notably, pharmaceutical companies are investing in the development of new long-acting injectables that not only ensure sustained therapeutic efficacy but also prioritize patient convenience. This shift reflects a broader understanding of the complexities of mental health treatment, emphasizing the need for solutions that are both effective and user-friendly, positioning long-acting injectables as key players in the market's growth.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Regulatory Landscape
- Patent Analysis
Global Antipsychotic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)
- Market Overview
- First Generation
- Second Generation
- Third Generation
Global Antipsychotic Drugs Market Size by Disease & CAGR (2025-2032)
- Market Overview
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Other Diseases
Global Antipsychotic Drugs Market Size by Drug & CAGR (2025-2032)
- Market Overview
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Brexpiprazole
- Paliperidone Palmitate
- Others
Global Antipsychotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Global Antipsychotic Drugs Market Size & CAGR (2025-2032)
- North America (Therapeutic Class, Disease, Drug, Distribution Channel)
- Europe (Therapeutic Class, Disease, Drug, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapeutic Class, Disease, Drug, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapeutic Class, Disease, Drug, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapeutic Class, Disease, Drug, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sumitomo Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkermes plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
